Clostridioides difficile is a spore-forming gram-positive bacteria and is the leading cause of antibiotic-associated diarrhea in hospitals worldwide. Immunocompromised conditions and disruptions of gut microbiota are risk factors for C. difficile infections (CDI). Currently no vaccines are available for the prevention of CDI and there are concerns for development of additional antibiotic resistance. In this study, we identified and characterized a bacteriocin from the probiotic Clostridium butyricum Miyari. Recombinant bacteriocin displayed a narrow spectrum of activity against only genus Clostridium and Clostridioides. Importantly, the recombinant bacteriocin displayed potent activity against C. difficile both in vitro and ex vivo. This study demonstrate the potential of developing alternative treatment strategies against CDI.
|Published - 22 Feb 2021
|Oklahoma State University Center for Health Sciences Research Days 2021: Poster presentation - Oklahoma State University Center for Health Sciences Campus, Tulsa, United States
Duration: 22 Feb 2021 → 26 Feb 2021
|Oklahoma State University Center for Health Sciences Research Days 2021
|22/02/21 → 26/02/21
- C. Difficile